BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11956544)

  • 1. Neck mass as primary manifestation of multiple myeloma originating in the thyroid cartilage.
    Gross M; Eliashar R; Petrova P; Goldfarb A; Sichel JY
    Otolaryngol Head Neck Surg; 2002 Mar; 126(3):326-8. PubMed ID: 11956544
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
    Piccinini L; Artusi T; Bonacorsi G; Arigliano V
    Haematologica; 2002 Feb; 87(2):EIM04. PubMed ID: 11836178
    [No Abstract]   [Full Text] [Related]  

  • 3. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
    Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
    Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
    [No Abstract]   [Full Text] [Related]  

  • 4. Bulbar palsy in multiple myeloma.
    Chim CS; Ooi GC
    Haematologica; 2005 Dec; 90(12 Suppl):ECR42. PubMed ID: 16464757
    [No Abstract]   [Full Text] [Related]  

  • 5. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
    Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
    Hönemann D; Prince HM; Seymour JF; Wolf MM; Westerman D; Januszewicz EH
    Leuk Lymphoma; 2005 Jun; 46(6):945-7. PubMed ID: 16019544
    [No Abstract]   [Full Text] [Related]  

  • 7. Alternating combination of alkylating agents and vincristine, doxorubicin, and dexamethasone in multiple myeloma.
    Lejeune C; Sotto JJ; Fuzibet JG; Rossi JF; Lepeu G; Bataille R
    J Clin Oncol; 1991 Jun; 9(6):1090-1. PubMed ID: 2033423
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.
    Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T
    Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiple myeloma complicated with Takotsubo cardiomyopathy].
    Mitsumori T; Nakajima K; Nozaki Y; Hamanaka S; Nagashima T; Kirito K; Iwao N; Komatsu N
    Rinsho Ketsueki; 2010 Apr; 51(4):291-6. PubMed ID: 20467228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma.
    Rostagno C; Ciolli S
    Ann Hematol; 2006 Sep; 85(9):627-8. PubMed ID: 16705455
    [No Abstract]   [Full Text] [Related]  

  • 11. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
    Chim CS; Choi PT; Lee WK
    Ann Hematol; 2013 Jun; 92(6):855-7. PubMed ID: 23183880
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pneumonia caused by Salmonella in a patient with myeloma].
    Fernández P; Roldán V; García MC; Gil MT; Rivas C
    Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
    Maniatis A; Stamatellou M; Papanastasiou K
    Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
    [No Abstract]   [Full Text] [Related]  

  • 14. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
    Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
    Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of multiple myeloma--associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone).
    Ichida M; Imagawa S; Ohmine K; Komatsu N; Hatake K; Ozawa K; Miura Y
    Int J Hematol; 2000 Dec; 72(4):491-3. PubMed ID: 11197218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma.
    Monconduit M; Le Loet X; Bernard JF; Michaux JL
    Br J Haematol; 1986 Jul; 63(3):599-601. PubMed ID: 3730288
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].
    Monconduit M; Le Loët X; Bernard JF; Menard JF; Grosbois B; Michaux JL; De Gramont A; Laporte JP; Najman A; Jouet JP
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):477-9. PubMed ID: 3616472
    [No Abstract]   [Full Text] [Related]  

  • 18. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
    van Rhee F
    Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.